Proliferative vitreoretinopathy

Lincolnshire Management Announces Acquisition of Whitewater Brands

Retrieved on: 
Monday, December 5, 2022
Finance, Automotive, Banking, Other Automotive, Professional Services, Logistics, Supply Chain Management, General Automotive, Transport, CHAMP, Lincolnshire Management, Transport, Management, Collection, Multisourcing, Proliferative vitreoretinopathy, Light, Growth, PricewaterhouseCoopers, Omnichannel, Marketing, Financial services, Car dealership, Schumacher

Lincolnshire Management, Inc. ("Lincolnshire") , a private equity firm focused on investing in and acquiring growing middle market companies across an array of industries, today announced the purchase of Whitewater Brands , LLC.

Key Points: 
  • Lincolnshire Management, Inc. ("Lincolnshire") , a private equity firm focused on investing in and acquiring growing middle market companies across an array of industries, today announced the purchase of Whitewater Brands , LLC.
  • "Lincolnshire has a track record of success investing in the transportation and transportation servicing industries so we bring significant experience and resources to Whitewater and the management team.
  • Under our ownership, we believe Whitewater has the potential to aggressively grow sales, explore collaboration across its existing brands, and utilize the Lincolnshire operations team to execute recognized efficiencies.
  • Headquartered in New York, Lincolnshire Management invests in acquisitions of private companies, recapitalizations, corporate divestitures, management buyouts and growth equity for public and private companies.

Global Proliferative Vitreoretinopathy (PVR) Drugs Pipeline Guide 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 20, 2022
Pharmaceutical, Health, Optical, Molecule, News, Mall of America, Proliferative vitreoretinopathy, Research, Therapy, Company, History, Discovery, R, Ophthalmology, SEC, Target, PVR, Decision-making, Petroleum, Pharmaceutical industry, Medical device

The pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.

Key Points: 
  • The pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.
  • The pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (PVR) therapeutics and enlists all their major and minor projects.

2021 Report on Proliferative Vitreoretinopathy (Ophthalmology) Drugs In Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 7, 2021
Health, Optical, Inflammation, History, Retinal detachment, Medication, Bleeding, Decision-making, Retina, R, Company, Diabetes, SEC, Proliferative vitreoretinopathy, Ophthalmology, News, Trauma, Mall of America, Health care, PVR, Therapy, Eye, Discovery, Research, ROA, Risk factor, Oil, Pharmaceutical industry, Surveying, Medical device, Marketing

The "Proliferative Vitreoretinopathy (PVR) (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Proliferative Vitreoretinopathy (PVR) (Ophthalmology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of the Proliferative Vitreoretinopathy (Ophthalmology) pipeline landscape.
  • The publisher's Pharmaceutical and Healthcare latest pipeline guide Proliferative Vitreoretinopathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Proliferative Vitreoretinopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.

Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy

Retrieved on: 
Monday, June 1, 2020
Oncology, Health, Stem cells, Clinical trials, Pharmaceutical, Optical, Biotechnology, Ophthalmology, Branches of biology, Vision, Geographic atrophy, Emerging technologies, Macular degeneration, Retina, Proliferative vitreoretinopathy, Gene therapy of the human retina

The loss of retina pigmented epithelium (RPE) cells over time creates progressively larger areas of atrophy in the adult retina, leading to impaired vision or complete blindness, a condition known as dry AMD.

Key Points: 
  • The loss of retina pigmented epithelium (RPE) cells over time creates progressively larger areas of atrophy in the adult retina, leading to impaired vision or complete blindness, a condition known as dry AMD.
  • The unique finding from the ongoing OpRegen clinical trial supports a different view, in which an RPE cell transplant can potentially replace or rescue retinal cells in patients who suffer from retinal lesions or degeneration.
  • We report evidence from a patient with atrophic end-stage disease who received a transplant of allogeneic RPE cells and showed substantial restoration of retinal tissue within the area of GA.
  • Any therapy which can save photoreceptors and RPE cells in areas of geographic atrophy would be very important to these patients.

Global Proliferative Vitreoretinopathy (PVR) Pipeline Study, H1 2020

Retrieved on: 
Monday, April 27, 2020
Vitreoretinopathy, Proliferative vitreoretinopathy, PVR, Retinopathy

DUBLIN, April 27, 2020 /PRNewswire/ -- The "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 27, 2020 /PRNewswire/ -- The "Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Aldeyra Therapeutics Announces First Patient Enrolled in the Phase 3 GUARD Trial for Prevention of Proliferative Vitreoretinopathy

Retrieved on: 
Thursday, December 19, 2019
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Health, Proliferative vitreoretinopathy, PVR, Clinical trial, Vitreoretinopathy, Medicine

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the Phase 3 GUARD Trial of ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR).

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient into the Phase 3 GUARD Trial of ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR).
  • Today, the only option for patients who develop PVR is surgery, which fails in a significant number of cases.
  • The GUARD Trial is a two-part, multi-center, randomized, controlled, adaptive Phase 3 clinical trial evaluating the efficacy of intravitreal injections of ADX-2191 versus standard-of-care for the prevention of PVR.
  • In September 2019, the U.S. Food and Drug Administration (FDA) granted fast track designation to ADX-2191 for the prevention of PVR.

Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Prevention of Proliferative Vitreoretinopathy

Retrieved on: 
Tuesday, September 24, 2019
Biotechnology, Pharmaceutical, Optical, FDA, Health, Clinical trials, Articles, Health, Life sciences, PVR, Vitreoretinopathy, Proliferative vitreoretinopathy, Retinopathy, Fast track, Orphan drug

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR).

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR).
  • Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients, said Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra.
  • The fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, potentially accelerating patient access to new therapies.
  • ADX-2191, an intravitreal formulation of methotrexate, has been granted orphan drug designation for the prevention of proliferative vitreoretinopathy (PVR).

Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, August 28, 2019
Biotechnology, Pharmaceutical, Optical, Health, General Health, Clinical trials, Medical specialties, Medicine, Organ systems, Vitreoretinopathy, Allergy, Allergic conjunctivitis, Retinopathy, Medication, Proliferative vitreoretinopathy

The Janney presentation will be webcast live and archived on the Investors section of the Aldeyra website, http://ir.aldeyra.com/ .

Key Points: 
  • The Janney presentation will be webcast live and archived on the Investors section of the Aldeyra website, http://ir.aldeyra.com/ .
  • Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.
  • Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjgren-Larsson Syndrome.
  • The company is also developing other product candidates for retinal and systemic inflammatory diseases.

Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis

Retrieved on: 
Tuesday, June 25, 2019
Research, Biotechnology, Pharmaceutical, Health, General Health, Other Science, Science, Medical specialties, Medicine, Immunology, RTT, Uveitis, Vitreoretinopathy, Allergy, Conjunctivitis, Retinopathy, Allergic conjunctivitis, Proliferative vitreoretinopathy, Biotechnology

( Nasdaq: ALDX ) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced results from the noninfectious anterior uveitis SOLACE Trial.

Key Points: 
  • ( Nasdaq: ALDX ) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced results from the noninfectious anterior uveitis SOLACE Trial.
  • We look forward to aggressively prioritizing advancement of high-value ocular programs in dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy.
  • After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for thirty days.
  • Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.

Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference

Retrieved on: 
Thursday, May 30, 2019
Medical specialties, Medicine, Vitreoretinopathy, Uveitis, Retinopathy, Proliferative vitreoretinopathy, Clinical medicine

LEXINGTON, Mass., May 30, 2019 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announcedthat Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 10:30 AM EDT at the Grand Hyatt in New York, NY.

Key Points: 
  • LEXINGTON, Mass., May 30, 2019 /PRNewswire/ --Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announcedthat Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 10:30 AM EDT at the Grand Hyatt in New York, NY.
  • Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.
  • Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjgren-Larsson Syndrome.
  • The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal diseases, post-transplant lymphoproliferative disease, autoimmune disease, metabolic disease, and cancer.